| Primary |
| Product Used For Unknown Indication |
31.4% |
| Drug Use For Unknown Indication |
8.3% |
| Sinusitis |
6.6% |
| Urinary Tract Infection |
5.9% |
| Cataract Operation |
5.5% |
| Pain |
5.0% |
| Prophylaxis |
5.0% |
| Hypertension |
3.7% |
| Bronchitis |
3.4% |
| Upper Respiratory Tract Infection |
3.2% |
| Pneumonia |
3.0% |
| Infection |
2.8% |
| Sepsis |
2.3% |
| Respiratory Tract Infection |
2.2% |
| Antibiotic Prophylaxis |
2.1% |
| Keratitis Fungal |
2.1% |
| Pharyngitis |
2.0% |
| Cough |
1.8% |
| Infection Prophylaxis |
1.8% |
| Psoriasis |
1.8% |
|
| Vomiting |
14.6% |
| Urticaria |
8.8% |
| Rash |
6.7% |
| Renal Failure Acute |
5.4% |
| Visual Acuity Reduced |
5.4% |
| Diarrhoea |
5.0% |
| Pruritus |
5.0% |
| Sepsis |
5.0% |
| Anaphylactic Shock |
4.2% |
| Angioedema |
4.2% |
| Nosocomial Infection |
4.2% |
| Pharmaceutical Product Complaint |
4.2% |
| Clostridium Difficile Colitis |
3.8% |
| Drug Interaction |
3.8% |
| Endophthalmitis |
3.8% |
| Pyrexia |
3.8% |
| Tachycardia |
3.3% |
| Toxic Epidermal Necrolysis |
3.3% |
| Anaphylactic Reaction |
2.9% |
| Hypotension |
2.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
23.0% |
| Product Used For Unknown Indication |
17.6% |
| Preoperative Care |
5.6% |
| Anaesthesia |
5.5% |
| Prophylaxis |
4.7% |
| Antibiotic Prophylaxis |
4.1% |
| Local Anaesthesia |
4.0% |
| Hypertension |
3.9% |
| Pain |
3.7% |
| Cataract Operation |
3.5% |
| Urinary Tract Infection |
3.3% |
| Chronic Obstructive Pulmonary Disease |
2.9% |
| Pneumonia |
2.6% |
| Pyrexia |
2.6% |
| Postoperative Care |
2.5% |
| Thrombosis Prophylaxis |
2.3% |
| Pharyngitis Streptococcal |
2.2% |
| Bacterial Infection |
2.1% |
| Foetal Exposure During Pregnancy |
2.1% |
| Osteitis |
2.0% |
|
| Toxic Epidermal Necrolysis |
17.6% |
| Visual Acuity Reduced |
10.0% |
| Endophthalmitis |
9.0% |
| Transaminases Increased |
5.9% |
| Clostridium Test Positive |
5.0% |
| Corneal Deposits |
4.5% |
| Renal Failure Acute |
4.1% |
| Thrombocytopenia |
4.1% |
| Urinary Tract Infection |
4.1% |
| Vomiting |
4.1% |
| Parophthalmia |
3.6% |
| Renal Failure |
3.6% |
| Anaphylactic Shock |
3.2% |
| Clostridium Difficile Colitis |
3.2% |
| Cytomegalovirus Infection |
3.2% |
| Diarrhoea |
3.2% |
| Sepsis |
3.2% |
| Septic Shock |
3.2% |
| Angioedema |
2.7% |
| Aspergillosis |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.8% |
| Drug Use For Unknown Indication |
11.4% |
| Pain |
5.5% |
| Hypertension |
5.0% |
| Prophylaxis |
3.8% |
| Coronary Artery Bypass |
2.8% |
| Multiple Myeloma |
2.5% |
| Infection |
2.4% |
| Thrombosis Prophylaxis |
2.4% |
| Infection Prophylaxis |
2.2% |
| Pneumonia |
2.1% |
| Pyrexia |
1.9% |
| Bronchitis |
1.8% |
| Crohn's Disease |
1.4% |
| Constipation |
1.4% |
| Diabetes Mellitus |
1.4% |
| Prophylaxis Against Transplant Rejection |
1.4% |
| Nausea |
1.3% |
| Depression |
1.3% |
| Anxiety |
1.3% |
|
| Vomiting |
9.6% |
| Urinary Tract Infection |
7.8% |
| Pain |
7.4% |
| Pneumonia |
6.9% |
| Pulmonary Embolism |
6.5% |
| Renal Failure Acute |
6.5% |
| Renal Failure |
6.3% |
| Sepsis |
6.1% |
| Injury |
5.2% |
| Pyrexia |
5.1% |
| Tachycardia |
4.3% |
| Unevaluable Event |
4.0% |
| Anxiety |
3.8% |
| Weight Decreased |
3.8% |
| Thrombocytopenia |
3.6% |
| White Blood Cell Count Decreased |
3.1% |
| Toxic Epidermal Necrolysis |
2.9% |
| Fear |
2.5% |
| Hypothermia |
2.3% |
| Sinusitis |
2.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
23.7% |
| Bronchitis |
13.6% |
| Hypertension |
10.2% |
| Asthma |
6.8% |
| Atrial Fibrillation |
6.8% |
| Pain |
6.8% |
| Diabetes Mellitus |
5.1% |
| Bronchitis Bacterial |
3.4% |
| Pneumonia |
3.4% |
| Sepsis |
3.4% |
| Anxiety |
1.7% |
| Anxiety Disorder |
1.7% |
| Arthropod Bite |
1.7% |
| Coronary Artery Disease |
1.7% |
| Gout |
1.7% |
| Hypothyroidism |
1.7% |
| Infantile Spasms |
1.7% |
| Infection Prophylaxis |
1.7% |
| Joint Arthroplasty |
1.7% |
| Nausea |
1.7% |
|
| Malaise |
18.2% |
| Arthropod Bite |
9.1% |
| Drug Interaction |
9.1% |
| International Normalised Ratio Increased |
9.1% |
| Off Label Use |
9.1% |
| Prothrombin Time Shortened |
9.1% |
| Pseudomembranous Colitis |
9.1% |
| Purulence |
9.1% |
| Pyroglutamate Increased |
9.1% |
| Stent Placement |
9.1% |
|
